Pooled analysis demonstrates favorable safety profile for risdiplam
Maria Mazurkiewicz-Bełdzińska outlines a pooled analysis of data from the FIREFISH, SUNFISH, and JEWELFISH trials, which demonstrates that risdiplam has a favorable benefit–risk profile in patients with spinal muscular atrophy (3:42).
Study shows real-world benefits of onasemnogene abeparvovec in younger SMA patients
Lena-Luise Becker discusses findings from a real-world study showing that spinal muscular atrophy patients younger than 8 months of age are the most likely to benefit from onasemnogene abeparvovec, while those older than 24 months have a lower likelihood of treatment response and a higher risk for side effects (4:22).
Telemedicine in rheumatology: COVID-19 and beyond
During the COVID-19 pandemic, the use of telehealth has increased in rheumatology practice, in line with many other areas of medicine, to enable healthcare delivery while reducing patients’ and providers’ risk for SARS-CoV-2 infection. Here we take a look at how telemedicine is used in rheumatology, explore the advantages and disadvantages, and outline what the […]
Rituximab use in the COVID-19 era: Striking the right balance
With rituximab-treated patients having an elevated risk for severe COVID-19 and a reduced likelihood of responding to vaccines, Sebastian Sattui and David Jayne discuss how these challenges can be addressed and explore the future role of the drug for the treatment of rheumatic diseases (13:17) https://www.youtube.com/embed/qdduVX3etQI 00:00 Introduction to the speakers00:26 The current situation with rituximab and […]
Time to reconsider the person with shortness of breath: EMPEROR-Preserved
https://www.youtube.com/watch?v=-m2mdihaKmY Recorded: Monday, October 11, 2021Broadcast: Thursday, October 21, 2021 Meet the faculty Alice Cheng Dr. Cheng is an Endocrinologist at Trillium Health Partners and Unity Health Toronto and an Associate Professor at the University of Toronto. Lars Rydén (Chair) Lars Rydén is Senior Professor of Cardiology at the Karolinska Institute, Stockholm, Sweden. He is […]
DKD treatment update: SGLT2 inhibitors and finerenone
Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes. https://www.youtube.com/watch?v=S8KG0pW1xsY 0:00 Introduction 1:40 The DAPA-CKD trial: Building on CREDENCE 5:01 How the trial findings will influence primary care 7:10 Safety […]
PEACE-1 points to benefit of adding abiraterone to ADT–docetaxel in de novo mCSPC
Karim Fizazi describes results from the phase 3 PEACE-1 trial suggesting that the combination of abiraterone, androgen deprivation therapy, and docetaxel could be an option for patients with a new diagnosis of metastatic castration-sensitive prostate cancer (5:58).
COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity
Jeffrey Sparks and Zachary Wallace talk about the potential for COVID-19 being more severe in rheumatoid arthritis patients treated with rituximab or JAK inhibitors rather than TNF inhibitors (8:06). https://www.youtube.com/embed/7C_6-gLT8os?modestbranding=0&rel=0 Transcript We performed our study among rheumatoid arthritis patients, all of whom had COVID-19 and all of which were being treated with either biologic or […]
COVID-19 vaccination in patients with cancer
We speak to medical oncologist Narjust Duma, from the University of Wisconsin in the USA, about COVID-19 vaccination in people with cancer, discussing issues such as the timing of vaccine administration, the importance of monitoring side effects, and the key unanswered research questions. Listen below or subscribe to this podcast on: Apple Podcasts | Spotify | Google Podcasts | Stitcher | TuneIn About […]
Metastatic urothelial cancer: clinical insights into trial data
Shilpa Gupta and Petros Grivas share their thoughts on the key practicing-changing trials in metastatic urothelial cancer, including EV-301, EV-201, TITAN-TCC, and TROPiCS-04, and discuss the emerging role of antibody–drug conjugates in the evolving treatment landscape (16:47). https://youtu.be/HZXI3u9jIR8